Press release
Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Cyclin Dependent Kinase Inhibitor Pipeline Report to explore emerging therapies, key Cyclin Dependent Kinase Inhibitor Companies, and future Cyclin Dependent Kinase Inhibitor treatment landscapes @ Cyclin Dependent Kinase Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cyclin Dependent Kinase Inhibitor Pipeline Report
* In January 2025:- Alliance for Clinical Trials in Oncology - This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
* DelveInsight's Cyclin Dependent Kinase Inhibitor pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Cyclin Dependent Kinase Inhibitor treatment.
* The leading Cyclin Dependent Kinase Inhibitor Companies such as Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group , and others.
* Promising Cyclin Dependent Kinase Inhibitor Therapies such as Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
Discover how the Cyclin Dependent Kinase Inhibitor treatment paradigm is evolving. Access DelveInsight's in-depth Cyclin Dependent Kinase Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin Dependent Kinase Inhibitor Emerging Drugs Profile
* Atirmociclib: Pfizer
Atirmociclib is a potential best-in-class, highly selective cyclin-dependent kinase 4 (CDK4) inhibitor currently in Phase III development by Pfizer for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). CDK4 is a protein that regulates cell division and is often overactive in certain types of breast cancer. By selectively inhibiting CDK4, atirmociclib can help slow or stop the growth of cancer cells. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Advanced or Metastatic Breast Cancer.
* BLU-222: Blueprint Medicines
BLU-222 is a highly selective and potent investigational CDK2 inhibitor with first- and best-in-class potential, designed by scientists at Blueprint Medicines. CDK2 is a cell cycle regulator and an important cancer target, with relevance in HR+/HER2- breast cancer and other malignancies, such as subsets of ovarian and endometrial cancer. Across multiple cancer types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor proliferation. Aberrant CCNE1 has been observed as a primary driver of disease, as well as a mechanism of resistance to CDK4/6 inhibitors. In HR+/HER2- breast cancer, the advent of CDK4/6 inhibitors has improved treatment; however, disease progression is nearly universal, and new innovation is needed to improve outcomes and prolong clinical benefit. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of HER2 negative breast cancer.
* SY-5609: Syros Pharmaceuticals
SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7), initially developed for select solid tumors. It has shown single-agent activity in various tumor types, including metastatic pancreatic cancer, characterized by prolonged stable disease and tumor shrinkage, uncommon in this refractory patient population. Combination with chemotherapy also demonstrated clinical activity, including a confirmed partial response in pancreatic cancer patients resistant to frontline therapy. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Advanced Solid Tumors.
* NKT 3447: NiKang Therapeutics
NKT-3447 is an investigational small molecule developed by NiKang Therapeutics, primarily targeting various metastatic solid tumors, including gastric cancer, ovarian cancer, and small-cell lung cancer. It functions as a selective inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a critical role in cell cycle regulation. By inhibiting CDK2, NKT-3447 aims to reduce cyclin E expression, a factor often amplified in several cancers. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Solid Tumors.
Get a detailed analysis of the latest innovations in the Cyclin Dependent Kinase Inhibitor pipeline. Explore DelveInsight's expert-driven report today! @ Cyclin Dependent Kinase Inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin Dependent Kinase Inhibitor Companies
Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group and others.
Cyclin Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Cyclin Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Cyclin Dependent Kinase Inhibitor Therapies and key Cyclin Dependent Kinase Inhibitor Developments @ Cyclin Dependent Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cyclin Dependent Kinase Inhibitor Pipeline Report
* Coverage- Global
* Cyclin Dependent Kinase Inhibitor Companies- Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group, and others.
* Cyclin Dependent Kinase Inhibitor Therapies- Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
* Cyclin Dependent Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cyclin Dependent Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Cyclin Dependent Kinase Inhibitor drug development? Find out in DelveInsight's exclusive Cyclin Dependent Kinase Inhibitor Pipeline Report-access it now! @ Cyclin Dependent Kinase Inhibitor Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cyclin-Dependent Kinase Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cyclin-Dependent Kinase Inhibitor - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atirmociclib: Pfizer
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Early Stage Products (Phase I)
* SY-5609: Syros Pharmaceuticals
* Preclinical Stage Products
* Drug Name: Company Name
* Inactive Products
* Cyclin-Dependent Kinase Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding
* Cyclin-Dependent Kinase Inhibitor - Unmet Needs
* Cyclin-Dependent Kinase Inhibitor - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cyclin-dependent-kinase-inhibitor-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
Legal Disclaimer:Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3860101 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Cyclin
Surging Prevalence Of Breast Cancer Fuels Expansion In The Cyclin-Dependent Kina …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Through 2025?
Recent years have seen an exponential growth in the market size of cyclin-dependent kinase (cdk) 4/6 inhibitor drugs. The market, currently valued at $12.35 billion in 2024, is projected to expand to $14.83…
Cyclin Dependent Kinase (CDK) Inhibitors Market - Current Impact to Make Big Cha …
The Cyclin Dependent Kinase (CDK) Inhibitors Market was valued at approximately USD 6.7 billion in 2023 and is projected to reach around USD 13.1 billion by 2033, growing at an estimated CAGR of 6.5% from 2024 to 2033.
Cyclin Dependent Kinase (CDK) Inhibitors Market Overview
The Cyclin Dependent Kinase (CDK) Inhibitors Market is witnessing steady growth driven by the increasing prevalence of various cancers, particularly breast cancer, and the rising demand for…
Surging Prevalence Of Breast Cancer Fuels Expansion In The Cyclin-Dependent Kina …
The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Size and Its Estimated Growth Rate?
The market for cyclin-dependent kinase (CDK) 4/6 inhibitor drugs has seen a significant surge…
Cyclin-Dependent Kinase Inhibitor Market Poised for Breakthrough Growth: Innovat …
The global Cyclin-Dependent Kinase (CDK) inhibitor market is entering an exciting chapter of expansion and innovation, driven by breakthroughs in cancer biology, an increasing pipeline of next-generation molecules, and strong commercial uptake of approved therapies. CDK inhibitors have emerged as a transformative class of targeted anticancer agents, disrupting key cell-cycle checkpoints that tumors rely on for uncontrolled proliferation. As precision oncology advances, the demand for CDK inhibitors is set to…
Cyclin Dependent Kinase Market Will Generate Record Revenue by 2029
Cyclin dependent kinase market is anticipated to grow at a significant CAGR during the forecast period. Cyclin-dependent kinases (CDKs) are protein kinases that are categorized by requiring a separate subunit, a cyclin. They provide domains essential for enzymatic activity and plays an important role in the control of cell division. Additionally, they modulate transcription in response to several extra- and intracellular cues. The major factor driving the growth of the…
Cyclin Dependent Kinase Market to Signify Strong Growth by 2023-2029
Cyclin dependent kinase market is anticipated to grow at a significant CAGR during the forecast period (2023-2029). Cyclin-dependent kinases (CDKs) are protein kinases that are categorized by requiring a separate subunit, a cyclin. They provide domains essential for enzymatic activity and plays an important role in the control of cell division. Additionally, they modulate transcription in response to several extra- and intracellular cues. The major factor driving the growth of…
